title: Biologics-based therapy for the treatment of rheumatoid arthritis.
abstract: Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells. In RA, biologics reduce joint inflammation, limit erosive damage, decrease disability, and improve quality of life. Infections are the main risk associated with their use. Because of the high prices of biologics, their cost-effectiveness is a matter of debate. They are mainly coadministered with disease-modifying drugs such as methotrexate when the latter are found to achieve insufficient disease control on their own.
authors.affiliation: Department of Rheumatology, King's College London School of Medicine, Weston Education Centre, London, UK. d.scott1@nhs.net
authors.forename: D L
authors.initials: DL
authors.lastname: Scott
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D001688:Biological Products / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products